Pokorska-Śpiewak Maria, Kowalik-Mikołajewska Barbara, Aniszewska Małgorzata, Pluta Magdalena, Marczyńska Magdalena
Department of Children's Infectious Diseases, Medical University of Warsaw, ul. Wolska 37, 01-201, Warsaw, Poland.
Hospital of Infectious Diseases, ul. Wolska 37, 01-201, Warsaw, Poland.
BMC Infect Dis. 2017 May 23;17(1):361. doi: 10.1186/s12879-017-2462-1.
There is a need for validation of noninvasive alternatives to liver biopsy for the evaluation of fibrosis in children with chronic hepatitis C (CHC). The aim of this study was to evaluate the diagnostic performance of serum biomarkers modified by the body mass index z-score (BMI z-score) for the detection of fibrosis and steatosis in children with CHC.
Thirty children aged 9.4 ± 3.7 years (14 males, 16 females) with CHC underwent liver biopsy. Fibrosis was scored using a 5-point METAVIR scale (≥2 = significant fibrosis). For all the children, the following noninvasive markers were calculated: The aspartate transaminase (AST)-to-platelets ratio index (APRI), the modified APRI (M-APRI: BMI z-score × APRI), the Fibrosis-4 index (FIB-4), the modified FIB-4 (M-FIB-4: BMI z-score × FIB-4), and a novel marker, B-AST (BMI z-score × AST). The area under the receiver operator characteristic curve (AUROC) was calculated to detect significant fibrosis and steatosis.
In the histopathological evaluation, 22/30 (73%) patients presented with fibrosis, and 8/30 (27%) presented with steatosis. For the detection of significant fibrosis, the AUROCs for M-APRI, M-FIB-4 and B-AST were 0.842, 0.823, and 0.848, respectively. For significant steatosis, the AUROCs were more than 0.9 for all markers that included the BMI z-score. B-AST, with a cut-off of 92.8, showed 71% sensitivity and 95% specificity for detecting significant fibrosis. For predicting severe steatosis, B-AST had 100% sensitivity and 92% specificity. Negative values of all three markers that included BMI z-scores excluded all patients with both significant fibrosis and significant steatosis.
Including the BMI z-score in serum biomarker formulas enhances their diagnostic ability to detect significant fibrosis and steatosis. B-AST may thus act as an effective alternative to liver biopsy.
对于慢性丙型肝炎(CHC)患儿,需要验证用于评估纤维化的肝活检无创替代方法。本研究的目的是评估经体重指数z评分(BMI z评分)修正的血清生物标志物对CHC患儿纤维化和脂肪变性的诊断性能。
30例年龄为9.4±3.7岁(男14例,女16例)的CHC患儿接受了肝活检。采用5分制METAVIR评分评估纤维化程度(≥2分为显著纤维化)。对所有患儿计算以下无创标志物:天冬氨酸转氨酶(AST)与血小板比值指数(APRI)、改良APRI(M-APRI:BMI z评分×APRI)、纤维化-4指数(FIB-4)、改良FIB-4(M-FIB-4:BMI z评分×FIB-4)以及一种新型标志物B-AST(BMI z评分×AST)。计算受试者操作特征曲线下面积(AUROC)以检测显著纤维化和脂肪变性。
在组织病理学评估中,22/30(约73%)例患者存在纤维化,8/30(约27%)例存在脂肪变性。对于显著纤维化的检测,M-APRI、M-FIB-4和B-AST的AUROC分别为0.842、0.823和0.848。对于显著脂肪变性,所有包含BMI z评分的标志物的AUROC均大于0.9。B-AST的截断值为9分,对显著纤维化的检测灵敏度为71%,特异度为95%。对于预测严重脂肪变性,B-AST的灵敏度为100%,特异度为92%。所有包含BMI z评分的三种标志物的阴性值可排除所有同时存在显著纤维化和显著脂肪变性的患者。
在血清生物标志物公式中纳入BMI z评分可提高其检测显著纤维化和脂肪变性的诊断能力。因此,B-AST可作为肝活检的有效替代方法。